Press Release

Presented at SCCT – New Plaque Clinical Data Provides Additional Insights on Anatomy and Physiology in Clinical Decision Making for Patients

MOUNTAIN VIEW, Calif. – July 21, 2022 — HeartFlow, Inc., the leader in revolutionizing precision heart care, released two datasets utilizing its HeartFlow Plaque technology. The first dataset – HeartFlow’s largest study to date – studied over 11,800 patients and enables physicians to understand a patient’s burden of coronary plaque compared to their age and sex-matched peers. The second dataset demonstrated that HeartFlow Plaque may be “a reasonable non-invasive alternative to invasive angiography for assessment of coronary plaque”.1 Both studies were presented at the 17th Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography (SCCT) in Las Vegas, NV, July 15-17th, 2022.

The “Nomographic CT Quantitative Plaque Data from a Large International Population”, presented by Georgios Tzimas, MD, University of British Columbia, Providence Health Care supported the clinical utility of being able to distinguish patients with high or low volumes of plaque across a population. HeartFlow Plaque* was applied to over 11,800 coronary computed tomography angiograms (CCTAs) and atherosclerotic plaque burden data were stratified by age and sex. Understanding how an individual patient compares to a real-world population can provide context for physicians as they consider the best treatment plan for an individual patient. The information may also help motivate patients to adhere to recommended medications or lifestyle modifications.

The “Quantitative Assessment Of AI-based CCTA Plaque Volume Compared With IVUS 2” presentation by Kersten Petersen, PhD, Senior Manager, Research, showed that HeartFlow Plaque agreed well with intravascular ultrasound(IVUS) measures of plaque volume (correlation coefficient of 0.92). This confirms that HeartFlow Plaque from CCTA is accurate when compared to IVUS and shows a strong correlation across a wide range of plaque volumes and types. By accurately quantifying the amount of plaque present in a patient’s coronary arteries, physicians can be provided with meaningful quantitative plaque information from CT images.

“We’ve known for years that atherosclerosis and coronary risk are multifactorial, reflecting aspects both of plaque burden and composition, as well as physiological influences. Understanding both plaque burden and physiology are imperative to assessing patient risk and optimizing treatment plans for patients with coronary artery disease,” said Campbell Rogers, MD, FACC, Chief Medical Officer, HeartFlow. “The new data reflect the company’s belief in the value of precise plaque information being additive to the critical physiological data we provide through FFRCT. We look forward to introducing HeartFlow Plaque* and working with physicians to understand better the interplay of plaque and physiology across the spectrum of coronary disease.”

*Currently pending 510(k) clearance from the Food and Drug Administration (FDA). Not available for sale.


About the HeartFlow FFRCT Analysis

Starting with a standard coronary computed tomography angiogram (CCTA), the HeartFlow Analysis leverages algorithms trained using deep learning (a form of AI) and highly trained analysts to create a digital, personalized 3D model of the heart. The HeartFlow Analysis then uses powerful computer algorithms to solve millions of complex equations to simulate blood flow and provides FFRCT values along the coronary arteries. This information is used by physicians in evaluating the impact a blockage may be having on blood flow and determine the optimal course of treatment for each patient. A positive FFRCT value(≤0.80) indicates that a coronary blockage is impeding blood flow to the heart muscle to a degree which may warrant invasive management.

Data demonstrating the safety, efficacy and cost-effectiveness of the HeartFlow Analysis have been published in more than 500 peer-reviewed publications, including long-term data out to five years.1 The HeartFlow Analysis offers the highest diagnostic performance available from a non-invasive test.3 To date, clinicians around the world have used the HeartFlow Analysis for more than 130,000 patients to aid in the diagnosis of heart disease.1

About HeartFlow Plaque* Overview

The HeartFlow Plaque overview will provide plaque volume and characterize the type of plaque present. The HeartFlow Plaque feature is based on a fully automated deep-learning (a form of AI) algorithm for characterizing and quantifying plaque. In an internal study, the HeartFlow Plaque* technology was found to be more reliable than expert CT readers in identifying different types of plaque and quantifying total plaque volume.4 By adding the plaque overview to the physiological information currently provided by the HeartFlow Analysis, physicians will gain a more comprehensive understanding of a patient’s coronary disease burden and support efficient risk stratification of patients who may be at high risk of death from a heart attack.

About HeartFlow

HeartFlow is the leader in revolutionizing precision heart care, uniquely combining human ingenuity with advanced technology. HeartFlow’s non-invasive HeartFlow FFRCT Analysis leverages artificial intelligence to create a personalized three-dimensional model of the heart. Clinicians can use this model to evaluate the impact a blockage has on blood flow and determine the best treatment for individual patients. HeartFlow’s technology is reflective of our Silicon Valley roots and incorporates over two decades of scientific evidence with the latest advances in artificial intelligence. The HeartFlow FFRCT Analysis is commercially available in the United States, UK, Canada, Europe and Japan. For more information, visit


For Investors:
Leigh Salvo or Jack Droogan
Gilmartin Group

For Media:
Linly Ku

  1. Data on file at HeartFlow
  2. Multi-modality Imaging in Acute Myocardial Infarction (MIAMI), Robert Safian, MD, Beaumont Hospital, Royal Oaks, MI
  3. Driessen, et al. J Am Coll Cardiol 2019; Norgaard, et al, Euro J Radiol 2015
  4. HeartFlow Formal Reproducibility Study. December 2021

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!


HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。


さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please apply for research grants through our online submission form.

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.